# Glaukos Corporation (GKOS) Stock Analysis: Target Price Insights and Growth Prospects

- Link: https://www.directorstalkinterviews.com/glaukos-corporation-gkos-stock-analysis-target-price-insights-and-growth-prospects/4121259898
- Published: 2026-08-10T10:23:30+01:00
- Author: Madison Wilson

Glaukos Corporation (NYSE: GKOS), a prominent player in the healthcare sector, specifically
within the medical devices industry, has recently captured significant attention
from investors due to its robust revenue growth and analyst ratings. The company,
headquartered in Aliso Viejo, California, is recognized for its innovative therapies
targeting glaucoma, corneal disorders, and retinal diseases.

Currently priced at $180.02, Glaukos has experienced a remarkable journey over the
past year, hitting its 52-week high with a range spanning from $74.67 to $180.02.
The latest price change of $9.03, representing a modest 0.05% uptick, suggests stability
and growing investor confidence in the stock.

Despite the absence of traditional valuation metrics such as P/E and PEG ratios,
Glaukos’s forward P/E ratio stands at a staggering 358.64. This high valuation suggests
the market’s anticipation of substantial future earnings growth, reflecting the 
company’s strategic position in a rapidly expanding market. However, investors should
approach this metric with caution, as it indicates that much of the anticipated 
growth is already priced into the stock.

The company’s financial performance is underscored by an impressive revenue growth
rate of 49.50%. Yet, Glaukos faces challenges in profitability, with an EPS of -
3.28 and a return on equity of -25.98%. These figures highlight the company’s investment
in growth and development, which is typical in the lifecycle of innovative tech-
driven companies within the medical field.

Glaukos does not currently offer a dividend, which aligns with its growth-focused
strategy, retaining earnings to fuel expansion and innovation. This is further evidenced
by its healthy free cash flow of $15.46 million, providing the company with the 
liquidity needed to continue its aggressive growth initiatives.

Analyst sentiment towards Glaukos remains overwhelmingly positive, with 13 buy ratings
and only one hold rating. The average target price of $193.62 suggests a potential
upside of 7.55%, indicating continued investor optimism about the company’s future
prospects. The target price range between $172.00 and $215.00 reflects a consensus
that Glaukos is poised for further growth.

Technically, Glaukos is showing strong momentum with a 50-day moving average of 
$142.90 and a 200-day moving average of $119.43. The RSI (14) of 69.56 suggests 
that the stock is approaching overbought territory, which investors should monitor
closely for potential short-term volatility.

Glaukos’s product portfolio, including the iStent devices and the iDose TR, positions
the company to address unmet needs in the treatment of glaucoma and other eye disorders.
Its innovative solutions, such as the iLink device for keratoconus and the ILution
platform for transdermal drug delivery, underscore its commitment to advancing ophthalmic
care.

For investors, Glaukos Corporation represents a compelling opportunity in the healthcare
sector, driven by its innovative product offerings and strong market position. While
the high forward P/E ratio and current lack of profitability warrant caution, the
company’s growth trajectory and favorable analyst ratings suggest significant potential
for long-term gains. As Glaukos continues to innovate and expand its market presence,
it remains a stock to watch for those seeking exposure to the future of medical 
technology.

Share on:
